Corcept Therapeutics posts Q3 earnings beat, keeps 2026 revenue guidance and awaits FDA decision
Corcept Therapeutics reported third‑quarter 2026 revenue of $340.5 million, a 64 % year‑over‑year increase, and adjusted earnings of $1.01 per share, both surpassing analyst estimates. The company reaffirmed its full‑year 2026 revenue guidance of $1.1 billion‑$1.2 billion, with a midpoint of $1.15 billion slightly above consensus. Shares fell about 4 % after hours as the unchanged guidance disappointed investors, while the firm awaits an FDA decision on its relacorilant NDA by December 17 2026.
Why it matters
The earnings beat confirms Corcept’s strong sales momentum, but the unchanged guidance limits upside for investors and contributed to a near‑5 % share‑price decline (the company said shares fell 3.9 %). The pending FDA decision on relacorilant could materially affect future revenue, especially as the company projects $3 billion‑$5 billion in Cushing’s‑related sales by 2030 (the company expects the decision by Dec 17 2026).
Key facts
- 1Q3 2026 revenue was $340.5 million. tradingview.com
- 2Adjusted earnings per share were $1.01, beating the $0.79 consensus. investing.com
- 3Revenue grew 64 % year‑over‑year. finance.yahoo.com
- 4Full‑year 2026 revenue guidance remains $1.1 billion‑$1.2 billion, with a midpoint of $1.15 billion. investing.com
- 5The midpoint of $1.15 billion slightly exceeds the $1.14 billion analyst consensus. investing.com
- 6Net income for the quarter was $126.8 million. tradingview.com
Summary written by AlphAI AI Desk from 6 of 6 sources. Not investment advice. Figures are as stated by the linked sources.